The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis
Risiko endokriner immunvermittelter Nebenwirkungen unter PD-1-Inhibitoren bei Krebspatient:innen: systematische Übersicht und Metaanalyse
Frontiers in Oncology · 02.05.2024 · 14
DOI: 10.3389/fonc.2024.1381250 ↗Auf einen Blick
48 klinische Studien mit 24.514 Patient:innen zeigen unter PD-1-Inhibitoren ein erhöhtes Risiko für mehrere endokrine immunvermittelte Nebenwirkungen. Die Risiken unterschieden sich je nach Wirkstoff und Tumorart.
Fragestellung
Wie hoch ist das Risiko endokriner immunvermittelter Nebenwirkungen unter PD-1-Inhibitoren im Vergleich zu Kontrollbehandlungen?
Methode
Systematische Übersichtsarbeit und Metaanalyse von RCTs aus PubMed, Embase und Cochrane Library bis 24. November 2023; Vergleich mit Chemotherapie, zielgerichteter Therapie oder Placebo.
Ergebnisse
48 klinische Studien mit 24.514 Patient:innen. Unter PD-1-Inhibitoren erhöhtes Risiko für Hypothyreose, Hyperthyreose, Hypophysitis, Thyreoiditis, Diabetes mellitus und Nebenniereninsuffizienz. Für Pembrolizumab, Nivolumab, Tislelizumab und Sintilimab wurden erhöhte Risiken für einzelne Endokrinopathien berichtet.
Schlussfolgerung der Autor:innen
Das Risiko endokriner irAEs kann je nach PD-1-Inhibitor und Tumorart variieren. Für Kliniker:innen sind erhöhte Aufmerksamkeit und ein besseres Verständnis der Risikomuster wichtig.
Kernaussagen
- Unter PD-1-Inhibitoren traten mehrere endokrine irAEs häufiger auf.
- Die Risiken unterschieden sich je nach PD-1-Inhibitor.
- Auch die Tumorart beeinflusste einzelne Endokrinopathien.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 02.05.2024. Verfasst von Pengfei Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Weifang People's Hospital, Weifang, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege, Patientensicherheit
Abstract (Originalsprache)
Objective
Endocrinopathies are the most common immune-related adverse events (irAEs) observed during therapy with PD-1 inhibitors. In this study, we conducted a comprehensive systematic review and meta-analysis to evaluate the risk of immune-related endocrinopathies in patients treated with PD-1 inhibitors.
Methods
We performed a systematic search in the PubMed, Embase, and Cochrane Library databases to retrieve all randomized controlled trials (RCTs) involving PD-1 inhibitors, spanning from their inception to November 24, 2023. The comparative analysis encompassed patients undergoing chemotherapy, targeted therapy, or receiving placebo as control treatments. This study protocol has been registered with PROSPERO (CRD42023488303).
Results
A total of 48 clinical trials comprising 24,514 patients were included. Compared with control groups, patients treated with PD-1 inhibitors showed an increased risk of immune-related adverse events, including hypothyroidism, hyperthyroidism, hypophysitis, thyroiditis, diabetes mellitus, and adrenal insufficiency. Pembrolizumab was associated with an increased risk of all aforementioned endocrinopathies (hypothyroidism: RR=4.76, 95%CI: 3.55-6.39; hyperthyroidism: RR=9.69, 95%CI: 6.95-13.52; hypophysitis: RR=5.47, 95%CI: 2.73-10.97; thyroiditis: RR=5.95, 95%CI: 3.02-11.72; diabetes mellitus: RR=3.60, 95%CI: 1.65-7.88; adrenal insufficiency: RR=4.80, 95%CI: 2.60-8.88). Nivolumab was associated with an increased risk of hypothyroidism (RR=7.67, 95%CI: 5.00-11.75) and hyperthyroidism (RR=9.22, 95%CI: 4.71-18.04). Tislelizumab and sintilimab were associated with an increased risk of hypothyroidism (RR=19.07, 95%CI: 5.46-66.69 for tislelizumab and RR=18.36, 95%CI: 3.58-94.21 for sintilimab). For different tumor types, both hypothyroidism and hyperthyroidism were at high risks. Besides, patients with non-small cell lung cancer were at a higher risk of thyroiditis and adrenal insufficiency. Patients with melanoma were at a higher risk of hypophysitis and diabetes mellitus. Both low- and high-dose group increased risks of hypothyroidism and hyperthyroidism.
Conclusion
Risk of endocrine irAEs may vary in different PD-1 inhibitors and different tumor types. Increased awareness and understanding of the risk features of endocrine irAEs associated with PD-1 inhibitors is critical for clinicians. Systematic review registration crd.york.ac.uk/prospero , identifier PROSPERO (CRD42023488303).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Weifang People's Hospital, Weifang, China.
- Department of Pharmacy, Weifang People's Hospital, Weifang, China.
- Department of Rehabilitation Medicine & Department of Pharmacy, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China.
Zitieren
APA
Zhao, P., Zhao, T., Yu, L., Ma, W., Liu, W., & Zhang, C. (2024). The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1381250
Vancouver
Zhao P, Zhao T, Yu L, Ma W, Liu W, Zhang C. The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1381250
BibTeX
@article{Zhao2024,
author = {Zhao, Pengfei and Zhao, Ting and Yu, Lihong and Ma, Wenming and Liu, Wenyu and Zhang, Chenning},
title = {The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1381250}
}
EUVIMED